AbbVie Declares $1.73 Quarterly Dividend, Maintains Dividend Aristocrat Status

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.

Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

AbbVie's financial tables show a company with substantial revenue streams, particularly from its flagship products Skyrizi and Rinvoq, which together contributed to roughly 42% of the total net revenues in 2025. The company's strategic acquisitions, such as Cerevel and ImmunoGen, have further diversified its portfolio, positioning it for future growth.

The company's significant investment in research and development, as evidenced by its numerous compounds in clinical development, positions it well for future innovation and market leadership. AbbVie's integrated discovery and development teams enhance its ability to bring new, life-saving treatments to market, maintaining its competitive edge.

The acquisitions of Cerevel and ImmunoGen open doors for AbbVie to new therapeutic areas, such as neuroscience and additional oncology segments. These strategic moves not only diversify AbbVie's portfolio but also offer the opportunity to tap into new markets and patient populations.

However, the company faces potential vulnerabilities, including the looming expiration of key patents and the ever-present threat of biosimilars, which could impact future profitability. The company's reliance on patent protection for market exclusivity, particularly for its top revenue-generating products, exposes it to significant financial vulnerability once these patents expire.